Phase III Medical has named Robin L. Smith, MD, MBA as chairman of the board and CEO.

Alpharma has named Dean J. Mitchell president and CEO, effective July 1. Mitchell will succeed Ingrid Wiik, who previously announced she planned to retire as CEO once a successor was named.

Affibody AB has appointed Dr. Ulf Boberg CEO.

Quantum Genomics has appointed Lionel Ségard as CEO.

Isolagen has appointed Nicholas L. Teti, Jr. chairman and CEO.

David A. Evans Ph.D., CEO of WellGen, died on June 1 following a brief illness.

ACADIA Pharmaceuticals has named Roger G. Mills, M.D., as executive vice president, development.

Cardium Therapeutics has named Gabor M. Rubanyi, M.D., Ph.D. chief scientific officer.

Gloucester Pharmaceuticals has named Jean C. Nichols, Ph.D., as executive vice president and chief scientific officer.

Ablynx has appointed Eva-Lotta Allan as chief business officer.

Enzo Biochem has named Andrew R. Crescenzo senior vice president of finance.

Affymax has named Kay Slocum as senior vice president of human resources.

Rigel Pharmaceuticals has appointed Ryan D. Maynard vice president of finance and acting chief financial officer.

Cerimon Pharmaceuticals has appointed James H. Welch CFO.

Allos Therapeutics has named James V. Caruso as executive vice president, chief commercial officer.

EntreMed has appointed Cynthia Wong, Esq. as vice president, general counsel and secretary.

Corgentech has named K. Peony Yu, M.D., vice president of clinical research and Michael Leong, M.D., director of clinical research.

ZIOPHARM Oncology has appointed Brian Schwartz, M.D., as senior vice president for medical and regulatory affairs and chief medical officer.

AAIPharma has appointed Victoria Winters to the position of vice president of European business development.

NPS Pharmaceuticals has named Francois Nader, MD, as chief medical and commercial officer.

Human Genome Sciences has hired Margery B. Fischbein as vice president, business development and strategic planning.

Vical Incorporated has appointed Ronald B. Moss, M.D., vice president, clinical development.

AnorMED announced that Elisabeth Whiting, vice president of communications, had stepped down from her post.

Theresa Kennedy has joined ResVerlogix as vice president corporate communications.

Xceleron has elected Philip Morgan as non-executive chairman of the board.

Crucell Chairman Pieter Strijkert will step down and be succeeded by fellow Supervisory Board member Jan Oosterveld.

Altair Nanotechnologies has elected Pierre Lortie to its board of directors.

Phytopharm has named A. D. Morrison, former CEO of Lipton Ltd, a non-executive board director.

Stem Cell Innovations has elected Lucio A. Noto to its board of directors.

iCo Therapeutics announced the appointment of Dr. Richard W. Barker and William Jarosz to its board of directors.

Biomira announced that Dr. Alex McPherson has stepped down from the company's board.